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evaluate these as potential biomarkers for the differentia-
tion between dementia with Lewy bodies (DLB) and Alz-
heimer’s disease (AD).  Methods: We established H-FABP and 
tau protein values in a set of 144 persons with DLB (n = 33), 
Parkinson disease with dementia (PDD; n = 25), AD (n = 35) 
and nondemented neurological controls (NNC; n = 51). Ad-
ditionally, serum H-FABP levels were analyzed in idiopathic 
Parkinson disease patients without evidence of cognitive 
decline (n = 45) using commercially available enzyme-linked 
immunosorbent assays. We calculated absolute values of H-
FABP and tau protein in CSF and serum and established rela-
tive ratios between the two to obtain the best possible 
match for the clinical working diagnosis.  Results: Serum H-
FABP levels were elevated in DLB and PDD patients com-
pared with NNC and AD subjects. To better discriminate be-
tween DLB and AD, we calculated the ratio of serum H-FABP 
to CSF tau protein levels. At the arbitrary chosen cutoff ratio 
 6 8 this quotient reached a sensitivity of 91% and a specific-
ity of 66%.  Conclusion: Our results suggest that the mea-
surement of CSF tau protein, together with H-FABP quantifi-
cation in serum and CSF, and the ratio of serum H-FABP to 
CSF tau protein represent marker candidates for the differ-
entiation between AD and DLB. 
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 Abstract 
 Background: The measurement of biomarkers in cerebro-
spinal fluid (CSF) has gained increasing acceptance in estab-
lishing the diagnosis of some neurodegenerative diseases. 
Heart-type fatty acid-binding protein (H-FABP) was recently 
discovered in CSF and serum of patients with neurodegen-
erative diseases.  Objective: We investigated H-FABP in CSF 
and serum alone and in combination with CSF tau protein to 
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 Introduction 
 The distinction between dementia with Lewy bodies 
(DLB) and Alzheimer’s disease (AD) remains challenging 
due to the significant overlap in clinical signs  [1] . Today 
a definite diagnosis of the underlying neurodegenerative 
syndrome still requires neuropathological confirmation 
 [2–4] . Early and accurate diagnosis becomes more and 
more important, since novel and disease-specific inter-
vention trials are being planned, since unnecessary med-
ication and tests are to be avoided, and since the costs for 
dementia care soar  [5] . Biological markers supporting the 
clinical working diagnosis are often missing or do not 
meet requirements for routine standardization  [6, 7] .
 So far the differentiation between AD and DLB based 
on the quantification of select constituents in cerebrospi-
nal fluid (CSF) as potential surrogate markers, including 
of tau protein and   -amyloid 1–42, has shown unsatisfac-
tory results owing to the large overlap in values between 
the two syndromes  [8–10] . Nonetheless, total tau protein 
may contribute to the clinical distinction between the 
tauopathy of AD and the synucleinopathy of DLB  [8, 9] .
 Recently, heart-type fatty acid-binding protein (H-
FABP) was identified as a potential CSF biomarker for 
Creutzfeldt-Jakob disease (CJD)  [11] . Fatty acid-binding 
proteins (FABPs) are cytosolic 14- to 16-kDa proteins in-
volved in the uptake, transport and metabolism of fatty 
acids. FABPs are found in all cells that utilize fatty acids, 
and are known to be rapidly released into the extracellular 
space following cellular damage. H-FABP was initially pu-
rified from heart muscle and previously evaluated as a bio-
chemical marker of cardiac ischemia and brain injury  [12–
14] . H-FABP has been found to display a wide tissue distri-
bution including the expression in brain  [15] . Another 
FABP is   -synuclein, which is genetically and neuropatho-
logically linked to Parkinson disease (PD) and DLB  [16] , 
and was recently shown to function as a FABP-like con-
stituent of neurons, and to affect lipid metabolism in vivo 
 [15–21] .   -Synuclein-positive Lewy  bodies request a path-
ological hallmark of DLB and PD, and are also found in 
sympathetic neurons of the peripheral nervous system in-
cluding that of heart  [22] . Based on these findings, myo-
cardial scintigraphy using [ 123 I]metaiodobenzyl guanine 
has been investigated to help differentiate between synu-
cleinopathies and tauopathies  [23, 24] .
 In an independent pilot study of several degenerative 
dementias, high levels of CSF H-FABP were found in spo-
radic CJD patients and the highest number of H-FABP 
reactivity was observed in the serum of a small cohort of 
DLB patients  [25] .
 Accordingly, we carried out a cross-sectional study of 
H-FABP and tau protein levels in biological fluids of a 
cohort of patients with neurodegenerative diseases to 
evaluate their individual diagnostic value individually 
and to explore combinatorial ratios thereof for the pos-
sible distinction between AD and DLB.
 We hypothesized that H-FABP is a biomarker candi-
date not only for DLB but also possibly for Parkinson dis-
ease with dementia (PDD) given their virtually identical 
phenotype of central nervous system pathology. The bio-
chemical parallels between   -synuclein and H-FABP as 
well as several links between tau protein,   -synuclein and 
parkinsonism provided further impetus for our study 
 [19–21] . Here, we demonstrate that H-FABP together with 
CSF tau protein has the potential to be of use in the dif-
ferential diagnosis of several neurodegenerative diseases, 
especially the distinction between DLB and AD.
 Methods 
 Patients 
 We analyzed CSF and serum of 144 patients with DLB, PDD, 
AD and nondemented neurological controls (NNC). Addition-
ally, we examined serum of 45 patients with idiopathic Parkinson 
disease without dementia (IPD). All samples were drawn in the 
morning under fasting conditions. Routine laboratory investiga-
tions (e.g. liver enzymes, creatinine, creatine phosphokinase, lac-
tate dehydrogenase, total protein content in serum as well as com-
plete cell count and protein level in the CSF) were normal, and no 
patient showed signs of acute myocardial infarction (clinically or 
by laboratory investigations and electrocardiogram) or of overt 
congestive heart failure. In all patients either computed tomogra-
phy or magnetic resonance imaging of the brain was carried out 
to exclude structural entities.
 None of the patients included received medication known to 
potentially affect the lipid metabolism. In the case of evidence for 
another cause of dementia (e.g. recent or acute cardiac or cerebral 
infarction) subjects were excluded.
 Dementia with Lewy Bodies 
 Patients diagnosed as ‘probable DLB’ at a neurological univer-
sity hospital (according to the clinical classification criteria of 
McKeith et al.  [2, 3] ) were hospitalized for  6 24 h to evaluate them 
for fluctuating cognition, extrapyramidal symptoms and visual 
hallucinations. All DLB patients developed dementia before ex-
trapyramidal symptoms and were thus differentiated from PDD 
according to DLB guidelines  [2, 3] . We included 10 male and 23 
female DLB patients with a mean age of 70  8 9 years ( 8 SD; range 
66–86 years) ( table 1 ). Disease duration at the time of lumbar 
puncture (LP) was 24  8 21 months (range: 6–72 months). Mean 
MMSE was 14  8 5 points (range: 9 and 21 points; normal: 30).
 PDD and IPD 
 All PD patients were evaluated and their course followed in a 
specialized clinic for parkinsonism and movement disorders 
(Paracelsus-Elena Klinik, Kassel, Germany). The diagnosis was 
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made according to the UK Brain Bank diagnostic criteria for clin-
ically definite PD  [26] . All PD patients had suffered from idio-
pathic PD for at least 3 years prior to the occurrence of cognitive 
decline (in PDD cases) or showed no change in cognition (IPD).
 The Hoehn and Yahr (H&Y) score was used for classification 
of clinical disability  [27] . All PD patients were also evaluated us-
ing the motor subscale of the Unified Parkinson Disease Rating 
Scale (UPDRS part III, items 18–31) during their on-state  [28] . 
They all received treatment according to widely used practice 
guidelines  [29, 30] .
 PD patients were divided into two groups:
 (1) IPD patients: This group comprised 45 patients. All IPD 
patients had an MMSE  1 28 points and showed no signs of psy-
chosis or depression. 
 We included 45 patients (17 males and 28 females) with IPD of 
whom blood samples were available for H-FABP quantification 
( table 1 ). No CSF samples were available from these IPD patients. 
Mean age in this group was 69  8 10 years (range: 45–84 years). 
The duration of IPD was 231  8 96 months and ranged between 
24 and 444 months; classification according to H&Y was 3.5  8 1 
and ranged between 1 and 5, and the mean UPDRS score was 40 
 8 18 and ranged between 10 and 69. 
 (2) PDD patients: This group comprised 25 patients. All PDD 
fulfilled the DSM-IV criteria for dementia and presented with an 
MMSE  ^  25 points, thereby defining dementia. All patients were 
examined by a neurologist and either by a psychologist and/or psy-
chiatrist to exclude the diagnosis of depression. Subjects with 
MMSE  6 25 were excluded as were those with signs of depression. 
 We included 20 male and 5 female PDD patients with a mean 
age of 74  8 6 years (range: 56–84 years) ( table 1 ). Mean duration 
of PDD at the time of LP was 156  8 72 months (range: 48–336 
months). Mean MMSE was 18  8 7 points (range: 5–25 points). 
H&Y classification was 4  8 1 and ranged between 2 and 4; mean 
UPDRS (part III) was 49  8 13 and ranged between 30 and 83.
 Alzheimer’s Disease 
 We included patients with the diagnosis of AD recruited in the 
departments of psychiatry and neurology. The diagnosis of ‘prob-
able AD’ in all 34 cases was made according the DSM-IV criteria 
for dementia and the established NINCDS-ADRDA criteria  [31] . 
For 1 patient, neuropathological verification of AD was obtained 
postmortem using paraffin-embedded formalin fixation of brain 
tissue and immunohistochemistry. 
 We included 15 male and 20 female patients with AD ( table 1 ). 
Their mean age was 68  8 11 years and ranged between 63 and 85 
years. MMSE was 16  8 6 points (range: 3–24 points). Disease du-
ration was 44  8 25 months (range: 8–84 months). 
 Nondemented Neurological Controls 
 NNC patients underwent LP during routine workup of non-
dementing illnesses. These patients suffered from the following 
clinical working diagnoses: headache (n = 12), peripheral neuro-
logical diseases (n = 10), depression (n = 8), focal cerebral ischemia 
(n = 5), epileptic seizures (n = 3), amyotrophic lateral sclerosis 
(n = 2), dizziness (n = 2), myelopathy or radiculopathy (n = 6), 
and multiple sclerosis, small cell lung carcinoma without metas-
tasis to the central nervous system, and transient global amnesia 
(n = 3).
 Patients with cognitive changes and/or extrapyramidal signs 
were excluded from our study. There were 20 male and 31 female 
patients In the NNC group with a mean age of 67  8 12 years 
(range: 32–94 years) ( table 1 ). 
 Marker Measurement 
 Tau Protein 
 All specimens were obtained by LP, aliquoted and stored at
–80  °  C. All samples were analyzed using a commercially available 
enzyme-linked immunosorbent assay for tau protein (IN-
NOTEST hTAU Antigen, Innogenetics, Gent, Belgium)  [32–34] . 
Table 1. Demographics and phenotypic characterization of study participants
DLB
(n = 33)
PDD
(n = 25)
AD
(n = 35)
IPD
(n = 45)
NNC
(n = 51)
Age, years 7089 7486 68811 69810 67812
Range 66486 56484 63485 45484 32494
Median 72 74 65 68 66
Sex (male/total) 0.3 0.8 0.4 0.6 0.4
Duration of disease 24821 months 156872 months 44825 months 132896 months n.a.
Range 6472 months 484336 months 8484 months 244444 months
Median 14 months 132 months 40 months 120 months
MMSE 1485 1887 1686 >28 30
Range 9421 5425 3424
Median 14 11 40
UPDRS n.a. 49813 n.a. 40818 n.a.
Range 30483 10469
Median 48 46
Hoehn and Yahr n.a. 481 n.a. 3.581 n.a.
Range 245 145
Median 4 3.75
MMSE = Mini-Mental Status Examination; n.a. = not available.
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The signal corresponding to the lowest values for tau protein was 
equalized to the lowest standard concentration at 75 pg/ml. 
 H-FABP in CSF and Serum 
 H-FABP levels were measured in 25-  l aliquots of serum and 
50-  l aliquots of CSF, using a commercially available solid-phase 
enzyme-linked immunoassay based on the sandwich principle 
(HyCult Biotechnology, The Netherlands). Specificity of the anti-
bodies to H-FABP was previously established by Pelsers et al.  [35] , 
as cross-reactivity with non-H-FABP had been excluded. No per-
formance differences were observed in the FABP assay when ap-
plying serum or plasma; samples subjected to freeze and thaw 
cycles showed no loss of immunoreactivity  [36] . Signals corre-
sponding to the lowest values of H-FABP reactivity were set at the 
lowest standard concentration of 200 pg/ml of recombinant pro-
tein.
 The study was approved by the Ethics Committee of the Uni-
versity of Göttingen and the local board of registration of Hessen, 
Germany. Investigations were carried out with the informed con-
sent of all patients or their next of kin in the case of persons with 
dementia. 
 Statistical Analysis 
 Statistical analysis was performed applying the Mann-Whit-
ney test, when values from two cohorts were compared. For more 
than two groups the Kruskal-Wallis test was applied. To illustrate 
the variability of sensitivity and specificity for different cutoff lev-
els of the different marker combinations the receiver-operating 
characteristic (ROC) curve was computed. In addition, the area 
under the curve (AUC) for ROC curves was calculated. There, 
higher levels represented a better test performance  [37] . Only the 
best discriminating cutoff values alone or in combination are pre-
sented. Spearman correlations are given with p value and correla-
tions (c).
 To confirm results from our exploratory statistical approach, 
we conducted linear discriminant and logistic regression analy-
ses. This statistical approach was carried out by an experienced 
statistician (J.J.L.) using SAS. Logarithmic transformations of 
values (log) were used to meet assumptions of normality and ho-
mogeneity of variances for some of the statistical tests.
 Results  
 Tau Protein Levels in CSF 
 In diseased brains the mean CSF tau protein was 285 
 8 196 pg/ml (range: 75–973 pg/ml) for DLB, 248  8 141 
pg/ml (range: 99–702 pg/ml) in PDD and 949  8 1,821 
pg/ml (range: 75–11,152 pg/ml) in AD. Tau protein levels 
were 150  8 109 pg/ml (range: 75–583 pg/ml) in the con-
trol group (NNC) ( table 2 ,  fig. 1 ).
 Mean tau protein levels were significantly different be-
tween the cohorts of AD and DLB and AD and PDD (p  ! 
0.001) as well as between both DLB and AD and NNC 
(p  ! 0.001) as reported  [9] . At a reduced level of statistical 
significance, tau protein levels differed between PDD and 
NNC (p = 0.01). No difference was seen between PDD and 
DLB (p = 0.18) as expected, as they share nearly identical 
neuropathological phenotypes  [38, 39] .
 Total CSF tau protein was the most useful discrimi-
nating parameter at the best fit cutoff of 240 pg/ml be-
tween AD and NNC, with a sensitivity of 86% and a spec-
ificity of 92%.
 The patient with neuropathologically verified AD in 
our cohort had undergone LP 2 months after the onset of 
disease (4 years prior to death), and his CSF tau level was 
1,126 pg/ml.
 H-FABP Levels in CSF  
 To further discriminate between PDD, DLB and AD, 
we next examined CSF H-FABP levels ( tables 2 ,  fig. 1 ). In 
DLB, H-FABP was 1,511  8 843 pg/ml (range: 341–3,476 
pg/ml), in PDD 1,278  8 1,207 pg/ml (range: 100–6,400 
pg/ml) and in AD 1,607  8 950 pg/ml (range: 399–4,980 
pg/ml). In the NNC group, CSF H-FABP levels were 861 
 8 506 pg/ml (range: 100–2,507 pg/ml).
Table 2. Laboratory data according to working diagnosis
DLB PDD AD IPD NNC
Tau protein in CSF, pg/ml 2858196 2488141 94581,821 n.a. 1508109
Range 754973 994702 75411,152 754583
Median 220 192 691 116
H-FABP in CSF, pg/ml 1,5118843 1,27881,207 1,6078950 n.a. 8618506
Range 34143,476 10046,400 39944,980 10042,507
Median 1,283 1,283 1,542 800
H-FABP in serum, pg/ml 10,199815,526 6,69989,271 3,29982,090 2,71482,406 3,73486,824
Range 510489,688 1,824440,675 58149,029 288411,021 361435,683
Median 7,337 3,121 3,055 2,250 1,983
n.a. = Not available.
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 Accordingly, H-FABP levels were highly significantly 
different between DLB as well as AD and NNC (p  ! 
0.001). Statistical significance was also observed between 
PDD and NNC (p = 0.03), but did not differ between AD 
and DLB (p = 0.64), PDD and DLB (p = 0.16), and PDD 
and AD (p = 0.08). 
 H-FABP Levels in Serum 
 To pursue a higher order of diagnostic accuracy, we 
next determined serum H-FABP levels in our subjects. 
These were higher (mean: 10,199  8 15,526 pg/ml) and 
ranged between 510 and 89,688 pg/ml in DLB. In PDD, 
the mean serum H-FABP levels were 6,699  8 9,271 pg/ml 
(range: 1,824–40,675 pg/ml) and in AD cases 3,299  8 
2,090 pg/ml (range: 581–9,029 pg/ml). The NNC showed 
mean serum H-FABP levels of 3,734  8 6,824 pg/ml 
(range: 361–35,683 pg/ml) ( table 2 ,  fig. 1 ,  2 ). Thus, serum 
levels of H-FABP significantly differed between DLB and 
AD (p  ! 0.001) and between both PDD and DLB over 
NNC (p  ! 0.001). 
 The one patient with neuropathological verification of 
the clinical diagnosis of AD showed a serum H-FABP of 
5,923 pg/ml and a CSF H-FABP level of 2,419 pg/ml.
 Suspected Synucleinopathies 
 To further examine cohorts of clinically suspected 
synucleinopathies, we also investigated a group of IPD 
patients. Mean serum H-FABP levels were 2,714  8 2,406 
pg/ml (range: 288–11,021 pg/ml) ( table 2 ,  fig. 2 ). 
 Intriguingly, serum H-FABP levels were significantly 
different between PDD and DLB versus IPD (p  ! 0.001); 
however, no difference was seen between PDD and DLB 
(p = 0.14) as expected. Thus, in our cohort analyses, serum 
H-FABP alone could discriminate between parkinsonism 
with dementia versus classical PD without cognitive im-
pairment (e.g. PDD and DLB vs. IPD) ( fig. 2 ). Best cutoff 
points regarding the AUC varied among the clinical work-
ing diagnoses and reached sensitivities between 69 and 
92%, and specificities between 64 and 88% ( table 3 ).
 Combinational Analysis 
 To achieve a higher degree of specificity and sensitiv-
ity, and possibly allow a laboratory value-based distinc-
tion between our various cohorts, we next examined the 
usefulness of various combined test values.
 Ratios of H-FABP serum to CSF levels showed signifi-
cant differences between both the PDD and DLB groups 
CSF tau protein  
CSF H-FABP 
Serum H-FABP 
DLB PDD AD NNC 
75 
250 
500 
750 
2,500 
5,000 
7,500 
25,000 
p
g
/m
l
Median 25%–75% Area without extremes 
 Fig. 1. Logarithmic box plot of CSF tau 
protein and H-FABP in serum and CSF in 
DLB, PDD, AD and NNC. 
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versus AD (p = 0.003 and p  ! 0.001, respectively) ( table 3 , 
 fig. 3 ). Accordingly, the ratio of serum H-FABP to CSF 
tau showed highly significant differences between AD 
and DLB and successfully discriminated between both 
diseases at the chosen best-fit cutoff of  6 8.0, with a sen-
sitivity of 91% and a specificity of 66% ( table 3 ,  fig. 4 ). At 
a chosen cutoff of  6 9, this quotient discriminated be-
tween AD and PDD with a sensitivity of 88% and a spec-
ificity of 74% ( table 3 ,  fig. 3 ).
 Consistent with these results, logistic regression anal-
yses of individual and combinations of marker variables 
showed significant (p  ! 0.001) and optimal separation of 
IPD PDD DLB NNC AD
0
4,000
8,000
12,000
16,000
20,000
Se
ru
m
 H
-F
A
BP
 (p
g
/m
l)
 Fig. 2. Box plot of H-FABP in serum in 
IPD, PDD, DLB, NNC and AD. 
Table 3. Overview of the most informative parameters and chosen cutoff levels in correlation with working di-
agnosis
Working
diagnosis
Most informative parameter Best cutoff Sensitivity
%
Specificity
%
AUCa
DLB vs. AD serum H-FABP `4,000 pg/ml 71 69 0.799*
serum H-FABP/CSF H-FABP `3.3 80 74 0.779*
serum H-FABP/CSF tau protein `8.0 91 66 0.866*
DLB vs. PDD serum H-FABP `3,500 pg/ml 81 65 0.693
DLB vs. IPD serum H-FABPb `3,200 pg/ml 84 82 0.836*
DLB vs. NNC serum H-FABP `4,500 pg/ml 74 88 0.819*
PDD vs. AD serum H-FABP/CSF tau protein `9.0 88 74 0.840*
PDD vs. IPD serum H-FABPb `2,800 pg/ml 69 80 0.783*
PDD vs. NNC serum H-FABP `2,350 pg/ml 92 64 0.750*
AD vs. NNC CSF tau protein `240 pg/mlc 86 92 0.925*
* p values ~0.001.
a AUC according to the ROC curves [36]. 
b In 45 patients with IPD only serum was analyzed. 
c At cutoff 450 pg/ml [32, 33] sensitivity was 60% and specificity was 96%.
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DLB and AD with a linear combination of log CSF tau 
(coefficient = –1.58) and log serum H-FABP (1.35), each 
marker providing significant (p = 0.001) classification 
power beyond that of the other. This combination pro-
duced an AUC of 0.869 and reflected well the ratio be-
tween serum H-FABP and CSF tau protein with an AUC 
of 0.866 we introduced for practical reasons. 
 Discussion 
 We evaluated CSF tau protein together with H-FABP 
in CSF and serum in a larger group of patients suffering 
from neurodegenerative dementia, and compared these 
markers with NNC including subjects with idiopathic 
PD. Among the latter, we included subjects with and 
without dementia according to widely used clinical crite-
ria (see Methods section). Tau protein is an accepted 
marker in the differential diagnosis of neurodegenerative 
diseases  [40] , whereas H-FABP was only recently de-
scribed  [11] . Giving the intriguing parallels between H-
FABP and   -synuclein biology as well as the pathological 
links between   -synuclein and tau protein  [41] , we ana-
lyzed both H-FABP and tau-protein for their best-differ-
ential diagnostic potential for discriminating between 
DLB and AD by evaluating practical cutoff levels and ra-
tios. 
 Based on data with elevated CSF H-FABP and normal 
serum H-FABP values in 30 CJD patients (data not 
shown), we concluded that H-FABP proteins in CSF from 
CJD subjects are likely to originate from the brain and 
not from a peripheral source  [25] . In contrast, the high 
levels of serum H-FABP in DLB and PDD compared to 
IPD, NNC and AD (without corresponding H-FABP el-
evation in CSF) suggested that H-FABP dysregulation 
DLB PDD AD
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 Fig. 3. Box plot of quotient serum H-FABP/CSF tau protein in 
DLB, PDD, AD and NNC. * Neuropathologically verified AD pa-
tient. 
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 Fig. 4. ROC curves for the differential di-
agnosis of DLB versus AD using cutoff 
points and marker combinations. Best re-
sults (e.g. highest AUC) were obtained for 
the quotient of serum H-FABP/CSF tau 
protein. 
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was more likely related to a peripheral rather than neural 
source. 
 In none of our patients, was clinically or laboratory-
based cardiac dysfunction recognizable and no other or-
gan dysfunction could be identified.
 The generally held distinction between PDD and DLB 
rests on the observation that the disease begins with ei-
ther motor or cognitive signs, respectively, and that pro-
gression is more rapid and more widespread in DLB than 
in PDD. Neuropathologically, there is no substantive 
qualitative difference in their   -synucleinopathy pheno-
types  [39] .
 H-FABP is a member of a protein family found in 
brain as well as in heart tissue (from where H-FABP was 
initially purified)  [15] . Upon detection of release of H-
FABP from myocardial tissue following cellular damage, 
plasma H-FABP levels were explored as candidate mark-
er for myocardial ischemia  [12, 13, 35] . Elevated levels of 
brain-derived serum H-FABP were seen in patients fol-
lowing brain injury including cerebral ischemia and 
hemorrhage  [42–44] . However, these acute disease enti-
ties are less relevant in the case of chronically evolving 
neurodegenerative disease, and are therefore unlikely to 
present a diagnostic dilemma in the neurological prac-
tice setting.
 It is currently unknown whether elevated serum H-
FABP levels seen in DLB and PDD are the result of car-
diac involvement in the disease process or of systemic 
upregulation. Of note,   -synuclein-positive Lewy bodies 
are found in sympathetic neurons of the peripheral ner-
vous system including the conduction system of the 
heart, and these are frequently found abnormal in DLB 
and PD  [22, 23, 45] . These peripheral nervous system 
changes gave rise to the hypothesis of a peripheral start-
ing point for the disease  [38] . Importantly, future studies 
will further explore H-FABP levels in serum and CSF of 
synucleinopathy subjects, and will include the recently 
developed quantification of   -synuclein by ELISA
 [46–48] .
 A primary or secondary role of H-FABP in the wide-
spread synucleinopathies of PDD and DLB could under-
lie our observed laboratory changes, as   -synuclein has 
fatty acid-binding capacities, and a reciprocal interaction 
between polyunsaturated fatty acids and   -synuclein has 
recently been demonstrated in vivo  [19–21] . Therefore, 
H-FABP might be upregulated in concert with dysregu-
lated   -synuclein processing  [17, 18, 21] . It was also shown 
that H-FABP is associated with the dompamine D2 re-
ceptor  [49] . Future studies will address the systemic 
mRNA levels of H-FABP in our patient cohorts, and H-
FABP levels in cellular and animal models of synucle-
inopathies.
 Aside from the important pathophysiological ques-
tion, we have demonstrated a potential relevance of se-
rum and CSF H-FABP levels for clinical practice. The 
best discriminator for the clinically often challenging 
distinction between DLB and PDD over AD in our study 
was the ratio of serum H-FABP to CSF tau, where a larg-
er number suggested a higher probability of synucleinop-
athy in the clinical context of dementia ( fig. 3 ). Such a 
degree of discrimination is not yet possible with current-
ly investigated markers  [8–10] . To date, CSF markers 
(such as tau protein alone and in combination with   -
amyloid 1–42) fail to discriminate between AD and DLB 
because of a sizeable overlap and thus do not fulfil the 
requirements of a reliable biomarker  [7] . Future examina-
tion of additional cohorts may support the clinical sepa-
ration of AD from DLB (and PDD subjects) using serum 
H-FABP/CSF tau ratios. 
 We are aware of several potential weaknesses of our 
study: (1) its cross-sectional design and (2) the partial 
overlap seen between PDD and DLB groups versus our 
NNC cohort ( fig. 3 ). We will seek to address these in a 
prospective study with phenotypically well-character-
ized cohorts and include the quantification of CSF and 
blood   -synuclein levels  [46–48] . In contrast to other on-
going biomarker development efforts (e.g. functional and 
structural neuroimaging studies), our CSF and serum-
based assays for tau and H-FABP reactivities carry with 
them the potential benefit of a more universally applica-
ble and less expensive marker of DLB and PDD patholo-
gy, provided they can be validated in future studies.
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